MannKind | MNKD - La Marge Brute Sur Les Ventes





La Marge Brute Sur Les Ventes Changement Date
Adma Biologics USD 88.82M 13.19M 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Insmed USD 217.69M 106.25M 2025-12
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
MannKind USD 78.31M 76.21M 2025-12
Merck USD 10.85B 2.57B 2025-12
Minerva Neurosciences -4.27M 26.79M 2024-12
Novavax USD 125.04M 76.09M 2025-12
Novo Nordisk DKK 64.01B 1.19B 2025-06
Pfizer USD 12.28B 8.74B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
Xencor USD 21M 22.61M 2025-09